Generic placeholder image

Reviews on Recent Clinical Trials

Editor-in-Chief

ISSN (Print): 1574-8871
ISSN (Online): 1876-1038

Review Article

Early Docetaxel and Androgen Deprivation in the Treatment of Metastatic, Hormone-sensitive Prostate Cancer

Author(s): Davide Tassinari, Emiliano Tamburini, Lorenzo Gianni, Fabrizio Drudi, Manuela Fantini, Carlotta Santelmo, Lucia Stocchi, Francesco Montanari and Sergio Sartori

Volume 11 , Issue 4 , 2016

Page: [317 - 323] Pages: 7

DOI: 10.2174/1574887111666160719145456

Price: $65

Abstract

Background: To assess the role of docetaxel plus androgen deprivation in metastatic, hormone- sensitive prostate cancer.

Methods: A qualitative systematic review of literature was performed. All the randomized phase III trials comparing docetaxel plus androgen deprivation with androgen deprivation alone in patients with metastatic, hormone-sensitive prostate cancer were considered eligible and included into the analysis.

Results: Six papers (3 randomized clinical trials, and 3 systematic reviews with meta-analysis) were considered eligible and included into the analysis. A significant improvement in time to progression and OS in the entire population treated with docetaxel plus androgen deprivation was reported in all the trials and meta-analyses, and in two trials and all meta-analyses, respectively. One trial reported improvement of OS only in patients with high volume disease, and the meta-analysis that also analyzed the subgroups of patients with high or low volume disease reported a benefit of docetaxel plus androgen deprivation for either the entire population or the two subgroups of patients.

Conclusion: The early use of docetaxel combined with androgen deprivation improves the main outcomes in the treatment of metastatic, hormone-sensitive prostate cancer. The available data suggest that docetaxel plus androgen deprivation could be considered the novel standard for fit patients with metastatic, hormone-sensitive prostate cancer.

Keywords: Docetaxel, chemotherapy, prostate cancer, hormone-sensitive disease.


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy